RBCX Calculation Tool vs CARTOX

The Spectra Optia® Apheresis System RBCX Calculation Tool is intended to help medical professionals who are responsible for prescribing and performing red blood cell exchange (RBCX) procedures to estimate the volume of replacement fluid required to perform a procedure on the Spectra Optia system. Using the same patient data and the same fluid data that is entered on the Spectra Optia system, the RBCX Calculation Tool calculates and displays the estimated volume of replacement fluid required to achieve the target Hct and FCR. It can also determine whether a custom prime is recommended. While the tool is intended to help prepare for a procedure, it is not intended to be used for making medical decisions. Use of the Spectra Optia® Apheresis System RBCX Calculation Tool on iOS requires iOS version 14.0 or above. For more information about the tool, see the About page.

Cellular therapies can be associated with unique, acute toxicities which can be severe or even fatal if not identified early and treated appropriately. Cytokine Release Syndrome (CRS), the most commonly observed toxicity can range in severity from low-grade constitutional symptoms to high-grade syndrome associated with life-threatening multi-organ disfunction. Neurotoxicity, originally termed CRES (CAR-Related Encephalopathy Syndrome) and now updated to ICANS (Immune effector Cell-Associated Neurotoxicity Syndrome) is the second most-common adverse even and can occur concurrently with CRS. A multi-disciplinary working group was formed to address safety issues for patients receiving cellular therapy which led to the development of new grading methods and treatment algorithms that have been incorporated into the CARTOX mobile app. The CARTOX mobile app assists with grading toxicities, managing toxicities and assists with recommendations regarding appropriate antimicrobial prophylaxis for patients who have received immune effector cell therapy. Users are more easily able to determine if the patient is having cytokine release syndrome or neurotoxicity and to grade those toxicities. Intended audience: Clinicians (physicians, nurse practitioners, physician assistants, pharmacists, nurses) who treat/care for patients receiving immune effector cells.